Evidence map›Paper›PMID 34356272›Full record

ArticleHealthcare (Basel, Switzerland)2021

Clinical Factors Associated with COVID-19 Severity in Mexican Patients: Cross-Sectional Analysis from a Multicentric Hospital Study.

Joel Monárrez-Espino, Carolina Ivette Zubía-Nevárez, Lorena Reyes-Silva, Juan Pablo Castillo-Palencia, Julio Enrique Castañeda-Delgado, Ana Sofía Herrera van-Oostdam, Yamilé López-Hernández

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. [Risk factors at admission associated with intubation in patients with COVID-19].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joel Monárrez-EspinoDepartment of Health Research, Christus Muguerza del Parque Hospital, Chihuahua 31000, Mexico.ORCID 0000-0002-0695-5356
Carolina Ivette Zubía-NevárezVice Presidency of Health Sciences, Medical Specialties Program, University of Monterrey, San Pedro Garza García 66238, Mexico.
Lorena Reyes-SilvaDepartment of Health Research, Christus Muguerza del Parque Hospital, Chihuahua 31000, Mexico.
Juan Pablo Castillo-PalenciaGeneral Hospital of Soledad de Graciano Sánchez, San Luis Potosí Health Services, Soledad de Graciano Sánchez 78435, Mexico.
Julio Enrique Castañeda-DelgadoBiomedical Research Unit, Mexican Institute of Social Security, Zacatecas 98000, Mexico.ORCID 0000-0003-2124-2036
Ana Sofía Herrera van-OostdamBiochemistry Department, San Luis Potosí Autonomous University, San Luis Potosí 78290, Mexico.ORCID 0000-0002-5198-6100
Yamilé López-HernándezMetabolomics and Proteomics Laboratory, Mexican Council of Science and Technology, Zacatecas Autonomous University, Zacatecas 98000, Mexico.ORCID 0000-0002-1068-603X

Funding

Consejo Nacional de Innovación, Ciencia y Tecnología 311880
6 · The paper itself

Abstract

(1) Background: Latin America has been harshly hit by SARS-CoV-2, but reporting from this region is still incomplete. This study aimed at identifying and comparing clinical characteristics of patients with COVID-19 at different stages of disease severity. (2) Methods: Cross-sectional multicentric study. Individuals with nasopharyngeal PCR were categorized into four groups: (1) negative, (2) positive, not hospitalized, (3) positive, hospitalized with/without supplementary oxygen, and (4) positive, intubated. Clinical and laboratory data were compared, using group 1 as the reference. Multivariate multinomial logistic regression was used to compare adjusted odds ratios. (3) Results: Nine variables remained in the model, explaining 76% of the variability. Men had increased odds, from 1.90 (95%CI 0.87-4.15) in the comparison of 2 vs. 1, to 3.66 (1.12-11.9) in 4 vs. 1. Diabetes and obesity were strong predictors. For diabetes, the odds for groups 2, 3, and 4 were 1.56 (0.29-8.16), 12.8 (2.50-65.8), and 16.1 (2.87-90.2); for obesity, these were 0.79 (0.31-2.05), 3.38 (1.04-10.9), and 4.10 (1.16-14.4), respectively. Fever, myalgia/arthralgia, cough, dyspnea, and neutrophilia were associated with the more severe COVID-19 group. Anosmia/dysgeusia were more likely to occur in group 2 (25.5; 2.51-259). (4) Conclusion: The results point to relevant differences in clinical and laboratory features of COVID-19 by level of severity that can be used in medical practice.

Indexed as

COVID-19disease severityMexicomultivariate analysissigns and symptoms

Identifiers

PMID34356272
PMCPMC8307927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.